logo

We aspire to improve businness through technology for everyone we serve while reducing the total cost

Request a Quote Request a Quote
Contact Info

Corporate office : C-Wing, Sahyog Enclave, Umaya nagar, Nalasopara East, Thane - 401209

Monday - Fraiday, 9am - 5pm,

Saturday & Sunday - CLOSED

Latest News.

blog
  • 04 Jan 21
GLOBAL VACCINE ROLLOUT UNDERWAY AS COVID-19 CASES SURGE

As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data.

blog
  • 12 DEC 20
SEASONS GREETINGS FROM JANISTHA PHARMA

As we reach the end of an exceptionally challenging year, we want to wish you and your loved ones a joyful and peaceful festive season. We are looking forward to 2021 with renewed hope and belief that the new year will bring better things for us all. Warmest Seasons Greetings to you and yours from everyone at janistha Pharma! #seasonsgreetings #happyholidays #newyear2021

blog
  • 12 NOV 20
FDA OFFERS GUIDANCE TO ENHANCE DIVERSITY IN CLINICAL TRIALS

The guidance provides recommendations for sponsors on how to increase enrollment of underrepresented populations, guidance on broadening clinical trial eligibility criteria for clinical trials of investigational drugs intended to treat rare diseases and other considerations about the inclusion of important groups including racial and ethnic minorities, women and older people.

blog
  • 26 OCT 20
ORPHAN DRUGS MARKET TO REACH USD 340.84 BILLION BY 2027

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market in the coming years according to a new report from Fortune Business Insights.

blog
  • 16 Aug 20
OVER A THIRD OF ONCOLOGY TRIALS DISRUPTED BY COVID-19 RESUME: GLOBALDATA

More than one third of oncology trials disrupted by COVID-19 are now back according to the latest reports. This marks the largest no.of oncology trials resumed since the pandemic disruptions began. Oncology trials were seriously impacted by the virus causing many to be paused or suspended.

blog
  • 25 july 20
FDA PROPOSES NEW RULE ON REPORTING REQUIREMENTS TO SUPPORT RIGHT TO TRY

On July 23, the U.S. Food and Drug Administration (FDA) announced a new proposed rule that would require sponsors and manufacturers who provide an ‘‘eligible investigational drug’’ under the Right to Try Act to submit an annual summary of such use to FDA. The Right to Try Act (RTT)